Results 131 to 140 of about 4,805 (202)

Selinexor as a novel anti-cancer agent

, 2020
Selinexor as a novel anti-cancer agent, clinical trials, results and discussion on them.
openaire   +1 more source

CCT3-mediated regulation of XPO1/RB1 axis stability promotes cellular senescence and tumor progression in clear cell renal carcinoma. [PDF]

iScience
Cao Y, Xu C, Liu Y, Shi B, Li X, Li J, Zhang B, Zhang Z, Dai S, Sun Q, Gu J.   +10 more
europepmc   +1 more source

<i>KRAS</i> under attack: recent advances in targeted therapies involving G12C inhibitors and XPO1 inhibition. [PDF]

Transl Lung Cancer Res
Falk M, Schatz S, Tiemann M, Ficker JH, Brueckl WM.   +4 more
europepmc   +1 more source

Combined XPO1 Inhibition and Parthenolide Treatment Can Be Efficacious in Treating Triple-Negative Breast Cancer. [PDF]

Int J Mol Sci
Paulson AL, Elmorsi RM, Lee AM, Huang RS.   +3 more
europepmc   +1 more source

Inhibition of XPO1 by selinexor enhances terminal erythroid maturation through modulation of HSP70 trafficking in severe β0-thalassemia/HbE. [PDF]

PLoS One
Khamphikham P, Tantiworawit A, Anuchapreeda S.   +2 more
europepmc   +1 more source

XPO1 inhibition in KRAS-mutant cancers: time for clinical trials but how? [PDF]

Transl Lung Cancer Res
Nagasaka M, Khan HY, Luo F, Al-Hallak MN, Saif MW, Mohammad RM, Azmi AS.   +6 more
europepmc   +1 more source

Therapeutic synergies that overcome carboplatin resistance in triple-negative breast cancer. [PDF]

J Exp Clin Cancer Res
Altman JE, Valentine A, Dashti-Gibson N, Zboril EK, Boyd DC, Myrick RK, Olex AL, Dozmorov MG, Harrell JC.   +8 more
europepmc   +1 more source

Autophagy modulates glioblastoma cell sensitivity to Selinexor-mediated XPO1 inhibition. [PDF]

Neuro Oncol
Tang Y, Sprinzen L, Terada Y, Kiang KM, Li C, Zeng Y, Liu F, Zhou H, Liang X, Zhang J, Pieper RO, Chen B, Zhang L.   +12 more
europepmc   +1 more source

XPO1 R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance. [PDF]

Cancer Res
Totiger TM, Chiraphapphaiboon W, Baca Y, Chaudhry S, Notti RQ, Montoya S, Chojnacka M, Gaidosh G, Afaghani J, Affer M, Armstrong C, Kavanaugh PM, Karaca E, Zabroski J, Lewis M, Maye A, Jahn J, Soni RK, Bilbao D, Walker P, Elliott A, Lou E, El-Deiry WS, Rodriguez JA, Nguyen HD, Taylor J.   +25 more
europepmc   +1 more source

Cortical organoid-derived models of the melanoma brain metastatic niche enable prioritization of cancer-targeting drugs. [PDF]

Cell Rep Methods
Krieg K, Materna-Reichelt S, Naber T, Rachad FZ, Kauven P, Weller A, Haferkamp U, Wittich A, Zaliani A, Woo MS, Walkenhorst M, Siegmund M, Harberts J, Zierold R, Blick R, Conze C, Muschong P, Miltner D, Friese MA, Mezler M, Siegmund H, Evert K, Krasemann S, Gužvić NS, Klein CA, Werner-Klein M, Wegener J, Pless O.   +27 more
europepmc   +1 more source